Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.57 |
| ▸ | PPARA | Q07869 | 10/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365980 | 0.83 | PPARA (0.57) | PPARGPPARA | |
| SCHEMBL3362661 | 0.82 | METAP2 (0.49) | PPARGPPARAELANEMETAP2 | |
| SCHEMBL3361630 | 0.82 | METAP2 (0.47) | PPARGPPARAPPARDALDH1A1MAPT | |
| SCHEMBL3365817 | 0.81 | ATM (0.41) | PPARGPPARAHTTALDH1A1MAPT | |
| SCHEMBL3361632 | 0.80 | METAP2 (0.45) | PPARGPPARAPPARDMAPTELANE | |
| SCHEMBL8696194 | 0.78 | CTSS (0.53) | PPARGPPARAMAPT | |
| SCHEMBL8696199 | 0.78 | CTSS (0.53) | PPARGPPARAMAPT | |
| SCHEMBL28896972 | 0.78 | PPARG (0.65) | PPARGPPARAPPARDCYP1A2CYP2C9 | |
| SCHEMBL17713403 | 0.78 | CTSK (0.55) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL17713402 | 0.78 | CTSK (0.55) | PPARGPPARASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239268-A1 | Dipeptide derivatives | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20060058242-A1 | Dipeptide derivatives | FINK CYNTHIA A | 2006-03-16 | — | — | US | disclosed |
| US-6992105-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2006-01-31 | — | — | US | disclosed |
| US-20040235754-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-6777443-B2 | Dipeptide derivatives | NOVARTIS AG (CH) | 2004-08-17 | — | — | US | disclosed |
| EP-1392720-A2 | DIPEPTIDE DERIVATIVES HAVING A N-TERMINAL 2-THIOACYL GROUP AS VASOPEPTIDASE INHIBITORS | Novartis AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-20020183260-A1 | Dipeptide derivatives | NOVARTIS AG (CH) | 2002-12-05 | — | — | US | disclosed |
| WO-2002092622-A2 | DIPEPTIDE DERIVATIVES HAVING A N-TERMINAL 2-THIOACYL GROUP AS VASOPEPTIDASE INHIBITORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183260-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | PPARG 4882/4885PPARA 4863/4885PPARD 4681/4885 |
| US-20060058242-A1 | Dipeptide derivatives | ANPEP, ECE2, ECE1 | PPARG 4878/4885PPARA 4773/4885PPARD 4416/4885 |
| US-20040235754-A1 | Dipeptide derivatives | ANPEP, ECE1, ECE2 | PPARG 4882/4885PPARA 4863/4885PPARD 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.